A paper recently published in the New England Journal of Medicine and co-written by physicians and scientists at the University of Colorado School of Medicine finds that an important genetic risk factor for pulmonary fibrosis can be used to identify individuals at risk for this deadly lung disease.
[More]
The surgical management of non-small cell lung cancer in U.S. hospitals varies widely depending on the race of the patient, according to a new study.
[More]
Boehringer Ingelheim today announced data from Phase 2 and Phase 3 studies from the Company's ongoing clinical trial program investigating the efficacy and safety of tiotropium in asthma. These data were presented at the American Thoracic Society International Conference in Philadelphia, Pennsylvania.
[More]
The negative effects of poorly controlled asthma symptoms on sleep quality and academic performance in urban schoolchildren has been confirmed in a new study.
[More]
Research into genetic features of pulmonary fibrosis by physicians and scientists at the University of Colorado School of Medicine may lead to improved treatment of this deadly lung disease, according to a paper published online by JAMA.
[More]
WHO's Health Assembly, the world's largest health policy-making body, opened its 66th Session today in Geneva with around 3000 participants from around the world.
[More]
Gourmands and foodies everywhere have long recognized ginger as a great way to add a little peppery zing to both sweet and savory dishes; now, a study from researchers at Columbia University shows purified components of the spicy root also may have properties that help asthma patients breathe more easily.
[More]
Boehringer Ingelheim will contribute to advancing the scientific discussion in respiratory disease at the American Thoracic Society International Conference in Philadelphia, PA, May 17 – 22.
[More]
As part of the company's commitment to chronic obstructive pulmonary disease patients, Boehringer Ingelheim Pharmaceuticals, Inc., a leader in respiratory health, is updating healthcare professionals and patients that the transition to COMBIVENT RESPIMAT (ipratropium bromide and albuterol) Inhalation Spray for the maintenance treatment of COPD is nearly complete.
[More]
The U.S. Food and Drug Administration today approved Breo Ellipta (fluticasone furoate and vilanterol inhalation powder) for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease, including chronic bronchitis and/or emphysema.
[More]
A group of 40 students are part of Saint Louis University's Student National Medical Association chapter (SNMA), who are striving to reduce health disparities locally. This year, they received the Leadership in Institutional Diversity Award, a recognition given to a university for serving as an outstanding example of leadership and innovation in promoting and maintaining institutional diversity.
[More]
Adults with end-stage respiratory failure and pulmonary hypertension requiring ECMO (extracorporeal membrane oxygenation) have been "bridged" toward lung transplantation with novel lung assist devices such as the Novalung.
[More]
Almirall, S.A. (ALM:MC) and Forest Laboratories, Inc. (NYSE:FRX) today announced positive topline results from AUGMENT/COPD, the second six-month pivotal phase III clinical trial evaluating the efficacy and safety of investigational fixed dose combinations of aclidinium bromide (LAMA) and formoterol fumarate (LABA) for the treatment of Chronic Obstructive Pulmonary Disease (COPD), delivered in the Pressair™ inhaler (Genuair® outside the USA).
[More]
The Global Initiative for Chronic Obstructive Lung Disease classification of chronic obstructive pulmonary disease predicts mortality better than the 2011 ABCD scoring system, report Norwegian researchers.
[More]
Australian researchers have identified interferon-γ inducible protein-10 and neopterin as promising sputum markers of acute exacerbations of obstructive lung disease.
[More]
A recent Saint Louis University study revealed that Medicaid-insured children with eczema, an inflammatory skin condition that affects 20 percent children in the United States, do not have easy access to dermatologists.
[More]
When the automatic spending cuts kicked in for Medicare this month, every doctor saw a 2 percent reduction in reimbursement from the government insurance program. But cancer doctors have made the most noise
[More]
A new genome-wide association study of more than 6,000 people has identified seven new genetic regions associated with pulmonary fibrosis. In findings published online in Nature Genetics on April 14, 2013, researchers at National Jewish Health, the University of Colorado and several other institutions found a number of genes associated with host defense, cell-cell adhesion and DNA repair, which provide clues to possible mechanisms underlying this currently untreatable disease.
[More]
A new study looking at the genomes of more than 1,500 patients with idiopathic pulmonary fibrosis, a rare and devastating lung disease, found multiple genetic associations with the disease, including one gene variant that was linked to an increase in the risk of death.
[More]
Almirall, S.A. (ALM:MC) and Forest Laboratories, Inc. (NYSE:FRX) today announced positive topline results from a six month pivotal phase III clinical trial evaluating the efficacy and safety of fixed dose combinations of aclidinium bromide (LAMA) and formoterol fumarate (LABA) delivered by Almirall’s inhaler Genuair® (Pressair™ in the USA).
[More]